Neurology
-
Randomized Controlled Trial
Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study.
To determine the effect of erenumab, a human monoclonal antibody targeting the calcitonin gene-related peptide receptor, on health-related quality of life (HRQoL), headache impact, and disability in patients with chronic migraine (CM). ⋯ This study provides Class II evidence that for patients with CM, erenumab treatment improves HRQoL, headache impact, and disability.
-
Randomized Controlled Trial Comparative Study
Insular and anterior cingulate cortex deep stimulation for central neuropathic pain: Disassembling the percept of pain.
To compare the analgesic effects of stimulation of the anterior cingulate cortex (ACC) or the posterior superior insula (PSI) against sham deep (d) repetitive (r) transcranial magnetic stimulation (TMS) in patients with central neuropathic pain (CNP) after stroke or spinal cord injury in a randomized, double-blinded, sham-controlled, 3-arm parallel study. ⋯ NCT01932905.
-
Randomized Controlled Trial Multicenter Study
Photosensitive epilepsy: Robust clinical efficacy of a selective GABA potentiator.
The objective of this phase 2a study was to assess the activity of PF-06372865, a positive allosteric modulator (PAM) of α2/3/5 subunit-containing GABAA receptors with minimal activity at α1-containing receptors, which are believed to mediate many of the adverse events associated with benzodiazepines, in the epilepsy photosensitivity model as a proof-of-principle of efficacy. ⋯ This study provides Class II evidence that for people with a stable photoparoxysmal response to intermittent photic stimulation, PF-06372865 reduces the SPR.
-
Randomized Controlled Trial
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.
To evaluate the efficacy and safety of galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, in the preventive treatment of chronic migraine. ⋯ This interventional study provides Class I evidence that galcanezumab is superior to placebo in the reduction of the number of monthly MHDs.
-
Randomized Controlled Trial
Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial.
In this secondary analysis of the Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial, we report the effect of IV glyburide on adjudicated, edema-related endpoints. ⋯ This study provides Class II evidence that for patients with large hemispheric infarction, IV glyburide improves some edema-related endpoints.